Baseline Characteristics

Add MICARDIS^® Clinical Research to My Alerts (what's this?)

Print | Send to a friend

Demography/medical history

• Baseline demographic characteristics and medical history of the patients in the TRANSCEND^® study were generally comparable with those of patients in the HOPE trial – reflecting a study population who are at high risk of a cardiovascular event but with their blood pressure in the ‘normal’ range.^1-4
• However, patients in the TRANSCEND^® trial demonstrated greater ethnic diversity, were slightly older and had greater frequencies of hypertension and cardiovascular disease than those who participated in the HOPE study.^1-4 

Baseline characteristics in ONTARGET^® and TRANSCEND^® compared with the HOPE trial^1-4

	ONTARGET® (n=25,620)	TRANSCEND® (n=5,776)	HOPE (n=9,541)
Demography
Age (years)	66.4	66.9	65.9
Male (%)	73.3	57.1	73.3
Body Mass Index (kg/m2)	28.2	28.3	27.7
Waist-Hip Ratio	0.9	0.9	0.9
Medical History
Hypertension (%)	68.3	75.9	46.5
Myocardial Infarction (%)	48.7	46.2	52.8
Stable Angina (%)	34.8	36.0	55.8
Stroke / Transcient Ishaemic Attack (%)	20.7	22.1	10.8
Intermittent Claudication (%)	11.8	10.1	15.9
Diabetes (%)	37.3	35.4	38.3
Current Smoker (%)	12.5	9.8	14.1
Blood Pressure (mmHg)
At Run-In	143/82	142/82	139/79
At Randomization	134/77	135/78	-

Baseline characteristics indicate a study population at high risk of a cardiovascular event but with their blood pressure in the ‘normal’ range

 

Medications

• Use of beta-blockers or lipid-lowering therapy was higher in TRANSCEND® than in HOPE.^1-4 
• Almost 60% of the TRANSCEND^® population had already received ACE inhibitors, whereas in HOPE use of ACE inhibitors was negligible.^1-4 
• A high proportion of the study population was receiving drugs that can also lower blood pressure – a significant proportion of these were for secondary prevention rather than blood pressure control.^1-4     

Baseline medication use in ONTARGET^® and TRANSCEND^® compared with the HOPE trial^1-4

	ONTARGET® (n=25,620)	TRANSCEND® (n=5,776)	HOPE (n=9,541)
Antihypertensive Therapies
ACE Inhibitors (%)	57.5	58.1	11.6
ARBs (%)	8.6	29.9	-
Beta-Blockers (%)	56.9	57.9	39.5
Diuretics (%)	27.9	32.9	15.1
Dilitazem or Verapamil (%)	9.7	9.9	27.1
Other Calcium Channel Blockers (%)	23.8	31.2	20.5
Antithrombotic and Anticoagulant Therapies
Aspirin (%)	75.6	74.7	73.6
Ticlopidine (%)	2.5	2.6	4.8
Clopidogrel (%)	8.5	8.1	-
Oral Anticoagulants (%)	7.6	7.1	3.8
Other
Insulin (%)	10.4	7.2	11.7
Oral Hypoglycaemics (%)	25.0	23.8	21.8
Statins (%)	60.7	54.5	28.9
Nitrates (%)	29.2	33.9	31.1

Baseline medication use reflects current treatment practice The use of medications to lower blood pressure indicates that the effects of MICARDIS^® beyond good blood pressure control will be evaluated

References